Targeted radiation drug added to standard treatment in bid to stop prostate Cancer's return
NCT ID NCT05230251
Summary
This study tested a new approach for men whose prostate cancer returned after initial radiation treatment. It combined a standard internal radiation procedure (brachytherapy) with an experimental targeted radiation drug (177Lu-PSMA). The goal was to see if this combination could better control the cancer, both in the prostate and any hidden cells elsewhere, while being safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
London Health Sciences Centre
London, Ontario, N6A5W9, Canada
Conditions
Explore the condition pages connected to this study.